Our new Cryptocurrency section has arrived! Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValirx Share News (VAL)

Share Price Information for Valirx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.13
Bid: 0.12
Ask: 0.14
Change: 0.00 (0.00%)
Spread: 0.02 (16.67%)
Open: 0.13
High: 0.13
Low: 0.13
Yest. Close: 0.13
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

WINNERS & LOSERS SUMMARY: Rolls Royce Flies High With Planned Job Cuts

Thu, 14th Jun 2018 11:00

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

FTSE 100 - WINNERS

Rolls-Royce, up 2.6%. The jet engine maker said it will cut around 4,600 jobs as part of a business restructuring plan in order to save GBP400 million per annum by the end of 2020. Under the restructuring programme, the company aims to remove corporate management layers, complexity and duplication, including within its core engineering division, and replace a centralised decision and control structure by empowered business units having clearer accountabilities, and decision-making powers. The total cash cost of the restructuring programme is expected to be around GBP500 million, which will be incurred across 2018, 2019 and 2020.

GlaxoSmithKline, up 0.6%. The pharmaceutical firm said its joint venture ViiV Healthcare reported positive results in its two-drug regimen for the treatment of HIV. The GEMINI studies are part of ViiV Healthcare clinical trial for a two-drug regiment, involving the combination of dolutegravir and lamivudine medicines to treat HIV, as opposed to the standardised three-drug regimen. The UK pharmaceutical giant said the studies met their primary endpoint demonstrating "the potency, safety and tolerability of the dolutegravir plus lamivudine combination" and showing similar efficacy to the three-drug regimen. The studies seek to address long-term toxicity in people living with HIV by reducing the number of medicines used in their treatment, the company said.

WPP, up 0.7%. This was in spite of SocGen reducing the advertising firm's price target to 1,845 pence from 1,940p, but retaining its Buy rating. On Wednesday, WPP had expected to face serious investor pressure on its controversial pay award for founder and former Chief Executive Officer Martin Sorrell. Sorrell left the company in mid-April after the conclusion of an investigation into what WPP called "an allegation of misconduct" which it said did not "involve amounts that are material" to the company. At its annual general meeting on Wednesday, 27.2% of valid votes cast opposed its compensation committee report with 72.8% in favour.

FTSE 100 - LOSERS

RELX, down 3.7%. UBS cut the Anglo-Dutch business information and events company to a Sell rating from Neutral.

Pearson, down 3.2%. Barclays cut the housebuilder to an Underweight rating from Equal Weight, and reduced the price target to 815 pence from 855p.

Severn Trent, down 1.7%. The water company went ex-dividend, meaning that new buyers no longer qualify for the latest dividend payout.

FTSE 250 - WINNERS

AVEVA Group, up 13%. The electrical and industrial software provider reported a combined group pro forma pretax profit of GBP64.6 million for the year to the end of March, down from GBP98.3 million, on a revenue of GBP704.6 million and GBP648.7 million, respectively. This followed the recent combination with the software arm of France's Schneider Electric SA. Group profit, before tax and adjustments and on pro forma basis grew to GBP162.8 million from GBP152.4 million. The pro forma results include results for both heritage Schneider Electric Industrial Software Business and heritage AVEVA for the 12 months to March end, as well as for the comparative period.

Pets At Home, up 1.9%. This was in spite of Goldman Sacks cutting the pet product maker's price target to 145 pence from 198p, but retaining its Neutral rating.

FTSE 250 - LOSERS

PZ Cussons, down 5.5%. The consumer products group said Nigerian wages have continued to lag behind "significant cost inflation" in recent years, impacting most of PZ Cussons' Nigerian portfolio, PZ Cussons said. The company therefore expects pretax profit at the low end of its GBP80 million to GBP85 million guidance back in March. In financial 2017, pretax profit was GBP88.0 million. The company also struggled in the UK with product launches failing to make up for margin and volume shortfall. PZ Cussons's performance in the Australian, US and Indonesian markets was strong, however, it said. In response to challenging macroeconomic conditions, the company is embarking on a GBP10 million plan to reduce its overhead base and increase the speed at which new products are brought to market. PZ Cussons is also looking to reduce both the complexity of its projects and its product packaging.

FirstGroup, down 1.8%. HSBC cut the bus and train operator's price target to 80 pence from 111p, keeping its Hold rating.

OTHER MAIN MARKET AND AIM - WINNERS

Magnolia Petroleum, up 65%. The US-focused oil and gas company said it has agreed to sell all of its wells in North Dakota, which comes up to 31 wells for a total of USD1.5 million, as well as the sale of the Roger Swartz well in Oklahoma for USD30,000. The disposal is in line with Magnolia's debt reduction programme, and will clear a large part of the USD2.0 million balance of the reserve-based lending facility of its operating subsidiary, Magnolia Petroleum Inc.

ValiRx, up 20%. The biotechnology company said that the clinical trial for the anti-cancer compound VAL401 has been completed with the regulatory process moving towards completion as the Clinical Study report is on schedule for submission within the regulatory timeframe of two years from the rial approval. Advanced conversations have continued with prospective partners with the aim of securing a partnership to progress the project towards eventual patient use.

Vernalis, up 14%. The pharmaceutical company has terminated its development and commercialisation agreement with Tris Pharma Inc, and will pay back Tris USD10 million while being released from all future payment obligations under the agreement. Vernalis has also transferred the right to the product Tuzistra XR, including the New Drug Application. In addition, Vernalis said it has received several approaches from potential buyers to acquire the company itself.

OTHER MAIN MARKET AND AIM - LOSERS

Abenza, down 35%. The life sciences group said that at the time of the annual results release last Monday, it will need additional working capital within the next twelve months to support itself. To this end, Abzena has entered a non-binding heads of terms agreement to sell an interest in its entitlements to future royalties which may arise from certain Abzena Inside products.

Audioboom Group, down 27%. The audio-on-demand platform's shares were restored to trading, following news that the first year of its strategic partnership with Spotify Technology SA to the end of May led to a 10% increase in inventory listens from the use of its 1% of Audioboom's content over the period. In addition, Audioboom signed an agreement with Formula One Digital Media Ltd to launch an exclusive weekly podcast known as "Beyond The Grid", which will be focused on the car racing sport.

Faron Pharmaceuticals, down 18%. The biopharmaceutical company said that data from the Phase III INTEREST trial of Traumakine for the treatment of Acute Respiratory Distress Syndrome showed that the treatment was inconsistent in its bioactivity across the treatment group of patients, with just one sub-group showing a reduced Day 28 mortality rate.

More News

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

28 Nov 19 16:13

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

28 Nov 19 15:57

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

14 Oct 19 13:44

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

26 Sep 19 11:43

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

24 Sep 19 12:40

ValiRx Prostate Cancer Drug VAL201 Still Meeting Endpoints

(Alliance News) - ValiRx PLC on Tuesday said its VAL201 lead compound is still meeting all of its published endpoints and is behaving as expected in prostate cancer.VAL201 has been as a and

10 Sep 19 13:45

ValiRx Granted European Patent Allowance For VAL301 Compound

(Alliance News) - Clinical stage biotechnology firm ValiRx PLC said Thursday it has been granted a patent notice of allowance for its pre-clinical therapeutic compound, VAL301, from the European a

1 Aug 19 12:01

Monecor Takes Nearly 6% Holding In Biotechnology Firm ValiRx

(Alliance News) - ValiRx PLC on Tuesday said Monecor London Ltd now holds 5.7% interest in the biotechnology company.Prior to this transaction on Monday, Monecor's holding totalled were

23 Jul 19 16:25

US Grands Patent Claim For valiRx's VAL201 In Metastatic Cancer

(Alliance News) - ValiRx PLC on Wednesday said the US has allowed a patent claim for the use of VAL201 in metastatic cancer.Shares in ValiRx were down 7.1% at 0.21 pence in afternoon trade

26 Jun 19 14:30

ValiRx gets US patent protection for use of VAL201 peptide

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Wednesday that the US Patent and Trademark Office (USPTO) has allowed patent claims directed towards a method of preventing the worsening of symptoms of metastatic cancer, reducing the progression of metastatic cancer, or treating metastatic cancer - including prostate cancer - by administration of the 'VAL201' peptide.

26 Jun 19 10:53

ValiRx secures 'substantial amendment' to VAL201 clinical trials

(Sharecast News) - Clinical stage biotechnology company ValiRx updated the market on 'VAL201' on Thursday, confirming that, based on clinical results, a "substantial amendment" to the clinical trial protocol had received regulatory approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and the research ethics committee.

20 Jun 19 09:54

ValiRx Subscription Raises GBP300,000 For Drug Trial And Development (ALLISS)

(Alliance News) - ValiRx PLC on Thursday said it raised GBP300,000 via subscription for working capital and to progress the clinical trial of its VALL201 cancer drug.Shares in ValiRx a 31%

13 Jun 19 11:07

ValiRx In Discussions With Investor To End Subscription Agreement (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Monday confirmed it is in advanced discussions with European High Growth Opportunities SF to terminate a subscription agreement.Shares in the clinical

10 Jun 19 09:50

ValiRx Convertible Bond Talks In Advanced Stage; Plans Open Offer (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Wednesday said it is in advanced discussions with European High Growth Opportunities SF to enter a new convertible bond facility and is planning an open in a

5 Jun 19 10:54

ValiRx Extends Talks With Investor Over New Convertible Bond (ALLISS)

LONDON (Alliance News) - ValiRx PLC on Friday said it has extended the deadline to enter into a new convertible bond with European High Growth Opportunities SF to July 1.The cancer life was

31 May 19 12:04

Login to your account

Don't have an account? Click here to register.